34 stories found
Eli Lilly has officially launched its new oral weight-loss pill, Foundayo, in the United Kingdom. This marks the introduction of the medication to the UK market, with Seeking Alpha reporting on the launch.
Eli Lilly's new weight-loss pill, Foundayo, has received approval for use in the United Kingdom, making it the first European country to authorize the drug for weight control and Type 2 diabetes treatment.
Eli Lilly announced that its drugs Foundayo and Zepbound will be accessible to Medicare Part D beneficiaries starting July 1.
Eli Lilly and Company’s (LLY) drugs Foundayo and Zepbound are set to be covered for millions of Americans, expanding access to these treatments.
Wolfe Research suggests that the market's reaction to Eli Lilly's (LLY) Foundayo report appears to be excessive, indicating a potential overcorrection in the stock price.
Lilly's new oral weight loss pill, Foundayo, has shown strong early adoption, surpassing 5600 prescriptions in its third week on the market. This indicates a significant demand for the new pharmaceutical product.
Investors in Eli Lilly are keenly awaiting further information and insights regarding the drug Foundayo, following the release of its early launch data.
New obesity medications, Foundayo and Wegovy, are soon to be available in the UAE, prompting discussions about whether health insurance will cover their costs.
The UAE has become one of the first countries to approve Eli Lilly's once-daily oral obesity pill, Foundayo (orforglipron), a GLP-1 receptor agonist that mimics natural hormones to regulate appetite.
Rusia şi-a reafirmat, joi, disponibilitatea de a ajuta Iranul să scoată din ţară uraniul îmbogăţit dacă Republica Islamică va decide în cele din urmă acest lucru, informează EFE, potrivit Agerpres.
The FDA has granted approval for a new oral weight loss pill named Foundayo, with details released on its usage and implications.
The U.S. Food and Drug Administration has approved Eli Lilly's new oral GLP-1 weight loss pill, Foundayo, offering a convenient alternative to injections and expanding market options while intensifying competition with Novo Nordisk's Wegovy.
Foundayo, a new medication, has received approval in the United Kingdom for the treatment of both weight loss and type 2 diabetes, offering a new option for patients.
CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.
Eli Lilly and Company (LLY)'s drug Foundayo has reached a new weight loss milestone specifically among menopausal women, indicating its potential in this demographic.
CVS will soon cover Eli Lilly's GLP-1 medications, including Foundayo and Zepbound, potentially providing access to these drugs for millions more Americans.
Eli Lilly has projected its 2026 revenue to be between $82 billion and $85 billion, with non-GAAP earnings per share estimated at $35.50 to $37. These projections come as the company begins the launch of its new product, Foundayo.
Analysts remain bullish on Eli Lilly ahead of its Q1 earnings report, with particular focus on the company's obesity drug portfolio and the drug Foundayo. The preview suggests strong performance expectations driven by these key areas.
An article advises investors not to be concerned about the prospects of Eli Lilly (LLY) and Company's Foundayo treatment, implying positive outlooks for the drug.
Eli Lilly's Foundayo pill has demonstrated positive results in late-stage trials, showing it lowers heart attack and stroke risk. The company plans to seek FDA approval for the obesity pill in diabetes patients following its trial success.
An overview of the rapidly growing GLP-1 market details the costs of popular weight-loss medications like Wegovy, Zepbound, and Foundayo, and offers advice on choosing the best option.
Eli Lilly (LLY) has received FDA approval for its new weight management pill, Foundayo, marking a significant development in the treatment of obesity.
Eli Lilly's weight-loss pill Foundayo has received approval in the U.K., marking its first approval outside the U.S. and intensifying its competition with Novo Nordisk's Wegovy.
Novo Nordisk is gaining momentum with its Wegovy weight-loss pill, maintaining its lead against Eli Lilly's recently launched Foundayo in the competitive obesity treatment market.
Eli Lilly's stock extended its rally following positive results from the ACHIEVE-3 trial, which boosted the outlook for its drug Foundayo.
Research suggests that both the gut microbiome and Lilly's drug Foundayo can play a role in mitigating the "yo-yo diet" effect, where individuals regain lost weight. This indicates potential new avenues for weight management strategies.
Shares of pharmaceutical company Eli Lilly are under pressure following a report of a serious adverse event related to its drug, Foundayo.
Several major tech companies, including Meta and Microsoft, reported earnings, leading to significant fluctuations in their stock prices. Meta saw a substantial drop after its AI expense estimates, while Microsoft's solid earnings didn't prevent a stock decline.
Eli Lilly's stock experienced a decline following a challenging week for its drug Foundayo, while the FDA announced plans to issue vouchers to accelerate research into psychedelic-based medicines.
Eli Lilly's new drug, Foundayo, achieved 1,390 prescriptions during its first week on the market, according to a Reuters report.
In a late-stage trial involving over 2,700 adults, patients taking Lilly's obesity pill Foundayo showed a 16% lower risk of heart attack, stroke, or cardiovascular death.
Eli Lilly's new GLP-1 weight-loss pill, Foundayo, which is the first oral GLP-1 not requiring fasting, has been approved by the Food and Drug Administration and has shown effectiveness in clinical trials, with one user losing 25 pounds.
Eli Lilly's stock has seen a significant rise following the approval of its GLP-1 pill, intensifying competition in the weight-loss drug market with Novo Nordisk's Wegovy. Analysts continue to favor Eli Lilly's Foundayo, adding a financial dimension to the ongoing market battle and prompting investment discussions, with new approvals potentially marking a turning point for Novo Nordisk.